CanSino Biologics Balance Sheet Health
Financial Health criteria checks 4/6
CanSino Biologics has a total shareholder equity of CN¥5.1B and total debt of CN¥2.1B, which brings its debt-to-equity ratio to 41.3%. Its total assets and total liabilities are CN¥8.0B and CN¥2.9B respectively.
Key information
41.3%
Debt to equity ratio
CN¥2.09b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥3.28b |
| Equity | CN¥5.06b |
| Total liabilities | CN¥2.93b |
| Total assets | CN¥7.99b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: CASB.F's short term assets (CN¥4.4B) exceed its short term liabilities (CN¥1.8B).
Long Term Liabilities: CASB.F's short term assets (CN¥4.4B) exceed its long term liabilities (CN¥1.2B).
Debt to Equity History and Analysis
Debt Level: CASB.F has more cash than its total debt.
Reducing Debt: CASB.F's debt to equity ratio has increased from 9.9% to 41.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CASB.F has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CASB.F has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.